Advances in Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation’s Clinical & Research Conference, Endorsed by Leading Gastroenterology Professional Organizations
The Crohn’s & Colitis Foundation of America today announced that the American College of Gastroenterology (ACG); the American Gastroenterological Association (AGA); and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) have endorsed its 2010 Advances in Inflammatory Bowel Diseases, Clinical & Research Conference. The conference (www. advancesinibd. com) will take place December 9-12, 2010 at the Westin Diplomat Resort & Spa in Hollywood, Florida.
New York, NY (Vocus) September 1, 2010
The Crohn’s & Colitis Foundation of America today announced that the American College of Gastroenterology (ACG); the American Gastroenterological Association (AGA); and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) have endorsed its 2010 Advances in Inflammatory Bowel Diseases, Clinical & Research Conference. The conference (www. advancesinibd. com) will take place December 9-12, 2010 at the Westin Diplomat Resort & Spa in Hollywood, Florida.
The endorsements confirm the conference as a recommended event among each of the organization's members as well as clinicians and researchers seeking information about the chronic digestive diseases Crohn’s and colitis, collectively known as inflammatory bowel diseases (IBD). Through the endorsements, the Foundation, the leading nonprofit aimed at finding a cure for the 1.4 million Americans living with Crohn’s and ulcerative colitis, will be able to tap into a greater audience than ever before to get the word out about its annual conference and, in turn, help more patients affected by Crohn’s disease and ulcerative colitis.
“We are so grateful that the ACG, AGA, and NASPGHAN have endorsed the 2010 Advances in Inflammatory Bowel Diseases conference,” says Richard J. Geswell, President of the Crohn’s & Colitis Foundation. “The Advances conference makes it possible for clinicians and researchers from all over the world who are working to understand the causes of these often debilitating disease to come together to share and gain knowledge. These endorsements will provide greater exposure of the conference to new audiences in the gastroenterology community and reinforce the importance of past participants to return for this year’s program.”
The conference, developed and organized by Imedex®, is chaired by Richard P. MacDermott, MD, MACG of Albany Medical College and Stephen B. Hanauer, MD, FACG of the University of Chicago Medical Center. It has grown to become the “can’t miss” event for those who study and manage IBD patients. Attendees participate in the highest quality sessions presented by expert specialists and top thought leaders. New sessions and topics include expanded coverage of advances in IBD procedures and surgeries; expanded sessions on pediatric IBD; adaptive immunity; and more.
Visit www. advancesinibd. com for the agenda, to register, and to submit an abstract (abstract deadline September 7, 2010).
About Crohn's Disease & Ulcerative Colitis
Crohn's disease and ulcerative colitis are painful, medically incurable illnesses that attack the digestive system. Crohn's disease may attack anywhere from the mouth to the anus, while ulcerative colitis inflames only the large intestine (colon). Symptoms may include abdominal pain, persistent diarrhea, rectal bleeding, fever and weight loss. Many patients require hospitalization and surgery. These illnesses can cause severe complications, including colon cancer in patients with long-term disease. Some 1.4 million American adults and children suffer from Crohn's disease or ulcerative colitis, with as many as 150,000 under the age of 18. Most people develop the diseases between the ages of 15 and 35.
About the Crohn's & Colitis Foundation
The Crohn's & Colitis Foundation of America's mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. The Foundation ranks third among leading health non-profits in the percentage of expense devoted to research toward a cure, with more than 81 cents of every dollar the Foundation spends goes to mission-critical programs. The Foundation consistently meets the standards of organizations that monitor charities, including the Better Business Bureau's Wise Giving Alliance (give. org) and the American Institute of Philanthropy (charitywatch. org). For more information, contact the Foundation at 800-932-2423 or visit www. ccfa. org. Join CCFA on Facebook at http://apps. facebook. com/supportccfa/ (http://apps. facebook. com/supportccfa/) and follow CCFA on Twitter at www. twitter. com/ccfa (http://www. twitter. com/ccfa).
About Imedex
Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals. We develop high quality, scientific programming that translates the latest research into clinically relevant information. The activities have exceptional organization and outstanding educational value, with a proven sustained impact on disease management.
Our established relationships with the leading investigators and researchers in medicine, and some of the world's most prestigious societies, make our educational offerings the most effective in the industry. These specialists are widely recognized international authorities who provide fair and balanced presentations of the most clinically-significant and relevant information. At Imedex, we believe that education is the best medicine. ®www. imedex. com.
Media Contacts:
Ariella Levine
Crohn’s & Colitis Foundation
646-943-7430
Alevine(at)ccfa(dot)org
Heather Drew
Imedex
678.242.0927
H. drew(at)imedex(dot)com
###
